Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H30O4 |
Molecular Weight | 274.3963 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCC(=O)OCC(O)CO
InChI
InChIKey=ARIWANIATODDMH-UHFFFAOYSA-N
InChI=1S/C15H30O4/c1-2-3-4-5-6-7-8-9-10-11-15(18)19-13-14(17)12-16/h14,16-17H,2-13H2,1H3
Molecular Formula | C15H30O4 |
Molecular Weight | 274.3963 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.touroinstitute.com/natural%20bactericidal.pdf
http://www.naturalcurelabs.com/monolaurin-top-10/
Curator's Comment: description was created based on several sources, including:
http://www.touroinstitute.com/natural%20bactericidal.pdf
http://www.naturalcurelabs.com/monolaurin-top-10/
Monolaurin, derived naturally from coconut, is a source of the medium chain fatty acid lauric acid. Monolaurin has been widely researched for its antiviral, antibacterial, and antimicrobial properties, as it can break down and destroy the lipid layer of enveloped viruses where many pharmaceuticals fail. Fatty acids and monoglycerides produce their killing/inactivating effects by several mechanisms. An early postulated mechanism was the perturbing of the plasma membrane lipid bilayer. The antiviral action attributed to monolaurin is that of fluidizing the structure in the envelope of the virus, causing the disintegration of the microbial membrane. More recent studies, indicate that one antimicrobial effect in bacteria is related to monolaurin's interference with signal transduction/toxin formation. Another antimicrobial effect in viruses is due to lauric acid's interference with virus assembly and viral maturation. The third mode of action may be on the immune system itself. Monolaurin does not appear to have an adverse effect on desirable gut bacteria, but rather on only potentially pathogenic microorganisms. It is classified by the FDA as "generally regarded as safe" (GRAS).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P06886 Gene ID: NA Gene Symbol: tst Target Organism: Staphylococcus aureus |
|||
Target ID: CHEMBL4114 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8021206 |
|||
Target ID: CHEMBL1909490 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27366648 |
|||
Target ID: P01583 Gene ID: 3552.0 Gene Symbol: IL1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27366648 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Lauricidin Approved UseUnknown |
|||
Curative | Lauricidin Approved UseUnknown |
|||
Preventing | Lauricidin Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.lauricidin.com/instructions
The recommended initial level is ~0.75 gram or less two or three times daily for a week before increasing the amount. The level can be then increased to 1.5 grams one, two or three times daily thereafter. A maintenance level can be 3.0 grams two or three times a day necessary for optimum health effects. Take with or after meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4670656
MIC dose range of 1-Monolaurin for 10 susceptible organisms from groups A and D is 0,045 uM/ml - NI (not inhibitory at concentrations tested). Max concentration tested was 3,63 uM/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:10:49 GMT 2023
by
admin
on
Fri Dec 15 15:10:49 GMT 2023
|
Record UNII |
WR963Y5QYW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
698570
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
DTXSID5041275
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
205-526-6
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
1990422
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
142-18-7
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
75539
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
WR963Y5QYW
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
75543
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
WR963Y5QYW
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY | |||
|
14871
Created by
admin on Fri Dec 15 15:10:49 GMT 2023 , Edited by admin on Fri Dec 15 15:10:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Moderate biological activity against renal(A-498) and pancreatic(PACA-2) human tumor cells.
|